



17 July 2023

ASX ANNOUNCEMENT

ImpediMed Quarterly Results and Investor Conference Call Notification

ImpediMed Limited (**ImpediMed** or the **Company**) (ASX:IPD) advises it will release its Appendix 4C Cash Flow Statement and Quarterly Results for the period ending 30 June 2023, on Monday, 24 July 2023.

Investors are invited to join a live conference call and Q&A hosted by Managing Director and CEO, Rick Valencia at 9.30am (AEST) on Monday, 24 July 2023.

To pre-register, please follow this link:

<https://s1.c-conf.com/diamondpass/10031706-ya7ey.html>

Registered participants will receive a calendar notification with dial in details and a PIN for fast-track access to the call.

Approved for release by the Managing Director and CEO, Mr Rick Valencia.

Contact Details

Investor relations Contact:

Hannah Howlett

WE Communications

T: +61 (0) 4 5064 8064

E: investorrelations@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO[®] Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2023, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines[®]) for Survivorship were updated and reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex[®], ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit www.impedimed.com.